Share your thoughts on our News & Insights section. Complete our survey to help us improve.
Derren Nathan

Derren Nathan

Head of Equity Research

Derren leads our Equity Research team with more than 15 years of experience in his field. Derren enjoys exploring the complex pharmaceutical sector and presenting share ideas for retail investors. He focuses on identifying exceptional companies poised for long-term success through outstanding customer propositions, translating into potential market-beating growth or sustainable dividends.

Latest content from Derren

May 2025

Investing in weight-loss drug stocks – who are the frontrunners?
30th May 2025
Next week on the stock market
30th May 2025
NVIDIA: first quarter demonstrates strong underlying demand
29th May 2025
Pets at Home: full-year profit as expected but guidance lower this year
28th May 2025
Rio Tinto: Jakob Stausholm CEO to step down later this year
22nd May 2025
Mitchells & Butlers: strong first half, market remains robust
22nd May 2025
British Land: robust results but near-term outlook disappoints
22nd May 2025
Tate & Lyle: full year results meet expectations, soft outlook
22nd May 2025
Greggs: sales growth picks up after a slow start to the year
20th May 2025
Primary Health Properties: raises bid to £1.68bn to acquire Assura
19th May 2025
Novo Nordisk: CEO to step down due to market challenges
19th May 2025
Alibaba: Q4 profits grow, but cash flow comes under pressure
15th May 2025
Aviva: robust Q1, Direct Line deal expected to close mid-year
15th May 2025
Compass Group: full year guidance unchanged after strong first half
14th May 2025
Imperial Brands: full year guidance intact, more to do in H2
14th May 2025
Experian: More growth expected after topping margin guidance
14th May 2025
3 share ideas that could benefit from a truce in the trade war
13th May 2025
Next week on the stock market
9th May 2025
AMD: beats Q1 forecasts, China weighs on outlook
7th May 2025
Novo Nordisk: Strong first quarter but full-year guidance lowered
7th May 2025
J D Wetherspoon: Q3 sales rise
7th May 2025
Shell: Q1 profit beat and $3.5bn buyback
2nd May 2025
Next week on the stock market
2nd May 2025
Chevron: caution on buybacks after Q1 profit falls
2nd May 2025
Haleon: capital markets day update
2nd May 2025
Eli Lilly: sales targets intact after Q1 growth of 45%
1st May 2025
Whitbread: annual profit dips on soft demand for UK hotels
1st May 2025
Mastercard: strong Q1 with full year guidance intact
1st May 2025
CVS Group: sentiment rallies on initial CMA proposals
1st May 2025

April 2025

February 2025

Next week on the stock market
28th February 2025
CVS Group: UK drag continued in first half
27th February 2025
Haleon: launches new buyback with profits in line with estimates
27th February 2025
NVIDIA: another earnings beat in final quarter
27th February 2025
BP: financial strength prioritised in strategic reset
26th February 2025
Alibaba: unveils ambitious AI investment plans
25th February 2025
Smith & Nephew: 2024 beats lowered guidance
25th February 2025
Croda International: strategic progress in a challenging 2024
25th February 2025
Next week on the stock market
21st February 2025
Next week on the stock market
14th February 2025
British American Tobacco: final results and outlook reflect challenging market
13th February 2025
RELX: 2024 meets forecasts, further growth expected this year
13th February 2025
Heineken: buyback launched after earnings beat
12th February 2025
FTSE 100 nears record highs – 3 share ideas
12th February 2025
Entain: Gavin Isaacs steps down as CEO
11th February 2025
BP: Q4 profits slump with buybacks under review
11th February 2025
Coca-Cola: delivers strong Q4 performance with double digit growth
11th February 2025
McDonalds: Q4 revenues flat as US diners tighten belt
10th February 2025
AstraZeneca: strong final quarter drives full year revenue beat
6th February 2025
Compass: strong start to the year
6th February 2025
Eli Lilly: 2024 result and 2025 guidance both in-line
6th February 2025
GSK: enters 2025 in good health, launches £2bn buyback
5th February 2025
PayPal: Q4 profits beat forecasts, profit outlook disappoints
5th February 2025
Entain: BetMGM on course for breakeven point in 2025
5th February 2025
AMD: Strong Q4 but Data Center outlook disappoints
5th February 2025
Novo Nordisk: GLP1’s drive strong 2024 growth
5th February 2025
Diageo: tariff impacts overshadow first half progress
4th February 2025
Pfizer: 2025 guidance re-iterated after strong fourth quarter
4th February 2025

January 2025

Social handles

CV

Head of Equity Research

Hargreaves Lansdown

July 2022 - Present


Head of Research

Hybridian LLP

July 2018 - July 2022 • 4 yrs 1 mo


Investment research

Hybridian LLP

Apr 2014 - July 2022 • 8 yrs 4 mos

In the press

Press articles quoting or featuring our experts and spokespeople. Hargreaves Lansdown is not responsible for these articles’ content and accuracy and may not share the views of the author or publication listed below.

dailymail.co.uk
Chancellor Jeremy Hunt's plan to sell off NatWest shares 'could cost taxpayers £28bn'

morningstar.com
Traders boost bets on mid-2024 rate cut by Bank of England as U.K. jobs market cools

thisismoney.co.uk
Analysts eye more M&A for Britain's hospitality sector